Lipoxygenase Inhibitors - Pipeline Insight, 2021

Lipoxygenase Inhibitors - Pipeline Insight, 2021

  • February 2021 •
  • 80 pages •
  • Report ID: 6022132 •
  • Format: PDF
“Lipoxygenase Inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lipoxygenase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Lipoxygenase Inhibitors Understanding

Lipoxygenase Inhibitors: Overview
Lipoxygenase (LOX) is a kind of rate-limiting enzyme in the process of arachidonic acid metabolism into leukotriene (LT) which mediates the occurrence of inflammation. The inhibition of LOX can reduce LT, thereby producing an anti-inflammatory effect. Lipoxygenase (LOX) can catalyze fatty acid to produce a number of active metabolic products that are involved in a lot of vital diseases. For instance, type 1 and type 2 diabetes (or both), cardiovascular diseases, hypertension, renal diseases, and neurological conditions such as Alzheimer’s disease and Parkinson’s disease.
LOX inhibitors are developed more slowly than COX inhibitors due to a lack of specific structure of LOXs. Additionally, as a result of the coexistence of LOXs in the same organism, LOX inhibitors should be designed seriously so as to achieve the targeting effect. In particular, another regulatory domain that is different from the two known domains of the C-terminal catalytic domain and the N-terminal ?-barrel domain has been found, which will provide new ideas for the design of new LOX inhibitors.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Lipoxygenase Inhibitors R&D. The therapies under development are focused on novel approaches for Lipoxygenase Inhibitors.

Lipoxygenase Inhibitors Emerging Drugs Chapters
This segment of the Lipoxygenase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lipoxygenase Inhibitors Emerging Drugs
• Epeleuton: Afimmune
Epeleuton, previously named DS102, is 15-hydroxy eicosapentaenoic acid (15(S)-HEPE) ethyl ester, a second-generation synthetic n-3 fatty acid and derivative of an endogenous downstream metabolite of EPA. Epeleuton is a new chemical entity with additional therapeutic effects compared with other n-3 fatty acid. It acts as 5-lipoxygenase inhibitors and is currently in Phase II of clinical trial for Alcoholic hepatitis, Chronic obstructive pulmonary disease, Diabetic neuropathies, Hypertriglyceridaemia, Idiopathic pulmonary fibrosis, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Type 2 diabetes mellitus.

• Tipelukast: MediciNova
Tipelukast is being developed by MediciNova and is in Phase II forIdiopathic pulmonary fibrosis, Non-alcoholic steatohepatitis. It acts as 5-lipoxygenase inhibitors.
Further product details are provided in the report……..

Lipoxygenase Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Lipoxygenase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Lipoxygenase Inhibitors
There are approx. 10+ key companies which are developing the Lipoxygenase Inhibitors. The companies which have their Lipoxygenase Inhibitors drug candidates in the most advanced stage, i.e. phase II include, Afimmune.
• Phases
report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Lipoxygenase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lipoxygenase Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lipoxygenase Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lipoxygenase Inhibitors drugs.

Lipoxygenase Inhibitors Report Insights
• Lipoxygenase Inhibitors Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lipoxygenase Inhibitors Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Lipoxygenase Inhibitors drugs?
• How many Lipoxygenase Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Lipoxygenase Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lipoxygenase Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lipoxygenase Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Afimmune
• MediciNova
• Mariposa Health Limited
• MedWell Laboratories
• BioElectron Technology
• CSPC Ouyi Pharmaceutical
• Veralox Therapeutics
• Qurient Therapeutics

Key Products
• Epeleuton
• Tipelukast
• TA 270
• MW 001
• PTC 857
• Baicalein
• VLX 1005
• Research programme: 5-lipoxygenase inhibitors